| Company Name | Bayer Taiwan Co., Ltd. |
|---|---|
| Protocol Number | 20748 |
| Title of Study | Observational study evaluating the physical activity in a subset of damoctocog alfa pegol treated Hemophilia A patients who are enrolled in the HEM-POWR study. |
| Primary Objective | To evaluate the change in physical non-sedentary activity, as measured by the ActiGraph device, after 1, 2 and 3 years of treatment with damoctocog alfa pegol, in a subset of patients who are enrolled in the HEMPOWR study. |
| Number of Sites | 5 |
| Period of Study | From：2021 Q1 to：2025 Q2 |
| Number of Patients | 10人 |
| IRB Approval Date | CSH 2021/1/11 TCVGH 2021/1/14 KMUH 2020/12/29 SHH Under reviewing |
| Publication Plan / Date | 2026 Q2 |
